Haematological malignancies generally have a multitude of aberrations across the Genome. These include fusion genes, copy number alterations and somatic mutations. However, no one technology can efficiently assess all of these aberration types, making the profiling of haematological malignancies labour and time-intensive.
The genetic complexity of cancer cells in haematological malignancies requires a thorough approach to detect relevant changes. The identification of copy number losses and gains, LOH, cnLOH, clonal heterogeneity, and ploidy status, as well as mosaicism, are all critical for evaluating blood cancer samples to discover new biomarkers.
Indalo Bio can help you successfully test for haematological malignancies to provide your patients with an accurate clinical diagnosis.